67
Participants
Start Date
August 9, 2021
Primary Completion Date
February 27, 2025
Study Completion Date
February 27, 2025
BMS-986416
Specified dose on specified days
Nivolumab
Specified dose on specified days
Local Institution - 0043, Edegem
Local Institution - 0016, Ghent
Local Institution - 0003, Pittsburgh
Local Institution - 0005, Baltimore
Local Institution - 0006, Atlanta
Local Institution - 0004, Houston
Local Institution - 0025, Santiago
Local Institution - 0026, Santiago
Local Institution - 0024, Santiago
Local Institution - 0002, Hackensack
Local Institution - 0013, Cleveland
Local Institution - 0021, Ciudad Autónoma de Buenos Aires
Local Institution - 0027, ABB
Local Institution - 0022, CABA
Local Institution - 0009, Edmonton
Local Institution - 0008, Toronto
Local Institution - 0001, Montreal
Local Institution - 0010, Chuo-ku
Local Institution - 0020, Maastricht
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY